Technical Analysis for ENLV - Enlivex Therapeutics Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 4.18 | 1.70% | 0.07 |
ENLV closed up 1.7 percent on Monday, March 18, 2024, on 1.18 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Apr 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Calm After Storm | Range Contraction | 1.70% | |
NR7 | Range Contraction | 1.70% | |
Narrow Range Bar | Range Contraction | 1.70% | |
Upper Bollinger Band Walk | Strength | 1.70% | |
Inside Day | Range Contraction | 1.70% | |
Wide Bands | Range Expansion | 1.70% | |
Overbought Stochastic | Strength | 1.70% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 7 hours ago |
Rose Above Previous Day's High | about 7 hours ago |
Outside Day | about 7 hours ago |
Up 3% | about 7 hours ago |
Up 2% | about 7 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/01/2024
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Tumor Virotherapy Coronavirus Cytokine Inflammatory Conditions Cytokine Release Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Tumor Virotherapy Coronavirus Cytokine Inflammatory Conditions Cytokine Release Syndrome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.37 |
52 Week Low | 1.2 |
Average Volume | 77,371 |
200-Day Moving Average | 2.38 |
50-Day Moving Average | 3.14 |
20-Day Moving Average | 3.49 |
10-Day Moving Average | 3.85 |
Average True Range | 0.34 |
RSI (14) | 66.78 |
ADX | 33.1 |
+DI | 23.24 |
-DI | 13.92 |
Chandelier Exit (Long, 3 ATRs) | 3.34 |
Chandelier Exit (Short, 3 ATRs) | 3.81 |
Upper Bollinger Bands | 4.41 |
Lower Bollinger Band | 2.58 |
Percent B (%b) | 0.88 |
BandWidth | 52.41 |
MACD Line | 0.33 |
MACD Signal Line | 0.25 |
MACD Histogram | 0.076 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.66 | ||||
Resistance 3 (R3) | 4.64 | 4.45 | 4.58 | ||
Resistance 2 (R2) | 4.45 | 4.33 | 4.47 | 4.55 | |
Resistance 1 (R1) | 4.32 | 4.26 | 4.23 | 4.34 | 4.53 |
Pivot Point | 4.13 | 4.13 | 4.09 | 4.15 | 4.13 |
Support 1 (S1) | 4.00 | 4.01 | 3.91 | 4.02 | 3.83 |
Support 2 (S2) | 3.81 | 3.94 | 3.83 | 3.81 | |
Support 3 (S3) | 3.68 | 3.81 | 3.78 | ||
Support 4 (S4) | 3.70 |